A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

NCT00745823 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

775

Enrollment

INDUSTRY

Sponsor class

Stopped Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg once daily versus raltegravir 400 mg twice daily

Conditions

Interventions

DRUG: Comparator: Raltegravir 400 mg b.i.d.
DRUG: Experimental: Raltegravir 800 mg q.d.
DRUG: TRUVADA™

Sponsor

Merck Sharp & Dohme LLC